SAN FRANCISCO, May 20, 2018 /PRNewswire/ -- A multifaceted
approach to treating men with orchialgia and chronic pelvic pain
may lead to improvements in quality of life and less pain over
time, according to data being presented at the 113th
Annual Scientific Meeting of the American Urological Association
(AUA). These studies will be presented to the media during a
special press conference on Sunday, May
20 at 11:00 a.m. (PT) at the
Moscone Center in San Francisco,
CA. This session will be moderated by Jamin Brahmbhatt, MD, men's health specialist
and urologist with Orlando Health in Clermont, Florida.
Study Details
Publication #: PD62-08
Trigger Point Dry Needling as a Treatment for Orchialgia:
Orchialgia, also known as chronic testicular pain, is persistent
pain in the scrotum with no known organic cause. It can come on
suddenly with severe pain, or it may be chronic – lasting more than
three months – and come on gradually. Although orchialgia
historically has been a challenging condition to treat, researchers
in Virginia Beach, VA, set out to
examine if pelvic floor trigger point dry needling may be an
effective treatment option for men suffering with this
condition.
Analyzing 2009 to 2016 self-reported improvement data, as well
as NIH Chronic Prostatitis Symptom Index (NIH-CPSI) data from
patients who underwent dry needling as a component of physical
therapy, results showed:
- Eighty-five percent of patients who underwent dry needling
indicated their orchialgia improved.
- Average number of dry needling treatments was 4.6 for those who
improved and 6.5 for the 15 percent who reported no
improvement.
- Dry needling is an effective treatment for orchialgia and
should be a part of multi-modal physical therapy.
Study Details
Publication #: PD62-09
Physical Therapy for Orchialgia Effective in Previously
Treated Patients: Chronic testicular and pelvic pain can have a
negative impact on a patient's quality of life, including a reduced
desire for sexual activity. However, recent research and
treatment programs for these conditions have begun to focus on
musculoskeletal dysfunction, a possible overlooked origin of
testicular pain, as a major contributor to both conditions.
Management of musculoskeletal dysfunction includes pelvic floor
physical therapy, as well as other medical and surgical options. As
such, researchers set out to examine clinically reported outcomes
of patients who subsequently underwent physical therapy after going
through other treatments for orchialgia.
A retrospective review of patient data was conducted for men who
initially presented with orchialgia and were referred for pelvic
floor physical therapy between January
2009 and June 2016. Each
patient had a urologic assessment prior to physical therapy
referral and were evaluated and treated by a physical therapy team,
in accordance with any presenting musculoskeletal impairments. Past
treatments for orchialgia (non-steroidal anti-inflammatory drugs
(NSAIDs), antibiotics, surgery, nerve block, narcotics and previous
pelvic floor physical therapy) were assessed and NIH-CPSI data was
collected following pelvic floor physical therapy.
Results showed and improvement in NIH-CPSI pain and quality of
life categories for all patients who received previous orchialgia
treatment. This lead researchers to conclude physical therapy
serves as a valid and effective treatment option for men with
orchialgia who have undergone previous medical and surgical
interventions.
Study Details
Publication #: PD62-01
Daily Low Dose Tadalafil in Treatment of Chronic
Prostatitis/Chronic Pelvic Pain Syndrome: Randomized Controlled
Study of Efficacy and Safety: Chronic prostatitis, also known
as chronic pelvic pain syndrome, is a common problem for men that
does not have a clearly defined origin or definitive treatment.
Antibiotics may be prescribed if there is a bacterial infection,
but most often treatment options are aimed at decreasing pain,
discomfort and inflammation.
Tadalafil, commonly known by the brand names Cialis or Adcirca,
is a vasodialator used to treat erectile dysfunction and enlarged
prostate (benign prostatic hyperplasia) – it can also treat
pulmonary hypertension. The primary objective of this study was to
assess the safety and efficacy of treating chronic prostatitis with
a daily low dose of Tadalafil (5 mg) added to Levofloxacin, an
antibiotic used to treat bacterial infections.
A total of 108 patients with prostatitis, but without erectile
dysfunction, were randomized into two treatment groups: group I (54
patients) received Levofloxacin, and group II (54 patients)
received 5mg of Tadalafil added to Levofloxacin. Treatment lasted
four weeks in a single-blinded manner. Patients were evaluated
using NIH chronic prostatitis symptom index (NIH-CPSI) and
International index of erectile function (IIEF-5) filled at
baseline and after the end of treatment.
Results showed:
- No significant difference between both groups in baseline
assessment characteristics.
- When comparing both groups, a statistically significant
difference in favor of Tadalafil group was reported in the pain
domain (p <0.05), urinary symptom domain (p <0.05), total
NIH-CPSI score (p <0.01) and IIEF-5 score (p <0.01), but not
in the quality of life domain (p >0.05).
- In the Tadalafil group the mean percent reduction from baseline
to four weeks was significant in all the three domains and in the
total NIH-CPSI scores (-54.86%- p <0.001). However there was a
mean increase in the IIEF-5 score (9.95 % - p <0.001).
The study concluded low dose Tadalafil (5 mg) added to
Levofloxacin as treatment is well tolerated and significantly
improved chronic prostatitis/chronic pelvic pain syndrome related
symptoms.
"These studies show great promise for men around the world
struggling with the pain and reduced quality of life issues
associated with prostatitis, pelvic pain and orchialgia," said Dr.
Brahmbhatt. "The role of physical therapy and the importance of a
multifaceted approach to treating these conditions are very much
evident within the results of this research."
About the American Urological Association: The 113th
Annual Meeting of the American Urological Association takes place
May 18-21 at the Moscone Center in
San Francisco, CA. Founded
in 1902 and headquartered near Baltimore,
Maryland, the American Urological Association is a leading
advocate for the specialty of urology, and has more than 21,000
members throughout the world. The AUA is a premier urologic
association, providing invaluable support to the urologic community
as it pursues its mission of fostering the highest standards of
urologic care through education, research and the formulation of
health policy.
Contact:
Christine Frey, AUA
410-689-3731, cfrey@AUAnet.org
View original content with
multimedia:http://www.prnewswire.com/news-releases/studies-show-men-with-orchialgia-or-chronic-pelvic-pain-could-benefit-from-multifaceted-therapies-including-physical-therapy-low-doses-of-tadalafil-and-dry-needling-300651591.html
SOURCE American Urological Association